510(K) CLEARANCES 84 ▲14RECALLS POSTED 39 ▲27CLASS I 6 ▲2PMA DECISIONS 47 ▲11WEEK ENDING / FDA DATA AS OF
Medical Device
ManufacturingTHE TRADE PAPER OF THE FACTORY FLOOR
SUBSCRIBE / SIGN IN
K863317Substantially Equivalent

Enzygnost Anti-Vzv Igg Test

Behring Diagnostics, Inc., La Jolla CA / Traditional, Substantially Equivalent
FDA source (opens on fda.gov)

K863317 is the FDA 510(k) clearance record for ENZYGNOST ANTI-VZV IGG TEST, a class II device, cleared for Behring Diagnostics, Inc. on under FDA product code GQX (Antiserum, Cf, Varicella-Zoster). FDA records list 145 510(k) clearances for Behring Diagnostics, Inc., from to . As of , FDA records show no recalls naming K863317.

Clearance record

Decision date
Received
(239 days to decision)
Product code
GQX Antiserum, Cf, Varicella-Zoster
Regulation
21 CFR 866.3900
Device class
Class II
Review panel
Microbiology
Applicant
Behring Diagnostics, Inc. 10933 No Torrey Pines Rd., La Jolla CA
Third party review
No

Clearances, product code GQX

Trailing 12 months

FDA records hold no clearances under product code GQX in the trailing twelve months.

FDA records show no clearances under product code GQX in the twelve months to October 2026.
Show the numbers
Monthly 510(k) clearances under FDA product code GQX, trailing twelve months
MonthClearances
November 20250
December 20250
January 20260
February 20260
March 20260
April 20260
May 20260
June 20260
July 20260
August 20260
September 20260
October 20260